Compare Cytokinetics Inc (CYTK) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Wells Fargo & Co — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Wells Fargo & Co trades at $81.96 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 28.8× Cytokinetics Inc's market cap, and Wells Fargo & Co pays a 2.44% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Wells Fargo & Co for 87 Days on average.
| CYTK | WFC | |
|---|---|---|
Market Cap | $8.62B | $248.06B |
Volume | 2,594,626 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $87.26 | $96.40 |
52-Week Low | $54.76 | $73.42 |
Typical Hold Time | 19 Days | 87 Days |
Enterprise Value | $8.72B | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Wells Fargo (WFC) trades at $80.26, down 1.53% with a bearish technical signal. The stock shows strong fundamentals with revenue growth to $83.7B in 2025 and improving net margins to 25.49%. Recent positive developments include a credit rating upgrade to 'A-' by S&P and upcoming Q3 earnings. Valuation metrics appear attractive with P/E of 11.67 and P/B of 1.47, trading below the consensus price target of $99.13.
WFC presents a compelling value opportunity with solid profitability and analyst support (46.7% buy ratings), though near-term headwinds include recent earnings misses and bearish technical indicators. The bank's improving credit profile and stable outlook support long-term growth potential, but investors should monitor interest rate sensitivity and execution on earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
